AAAAAA

   
Results: 1-9 |
Results: 9
THE NEUROCOGNITIVE EFFECTS OF QUETIAPINE (SEROQUEL, ICI-204,636)
Authors: FLEMING K KALALI A YEH C VARGO DL THYRUM PT POTKIN SG
Citation: K. Fleming et al., THE NEUROCOGNITIVE EFFECTS OF QUETIAPINE (SEROQUEL, ICI-204,636), Schizophrenia research, 24(1-2), 1997, pp. 197-197
EFFECT OF ZAFIRLUKAST ON THE PHARMACOKINETICS OF R-WARFARIN AND S-WARFARIN IN HEALTHY-MEN
Authors: VARGO DL WILKINSON LA LASSETER K
Citation: Dl. Vargo et al., EFFECT OF ZAFIRLUKAST ON THE PHARMACOKINETICS OF R-WARFARIN AND S-WARFARIN IN HEALTHY-MEN, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 86-86
DOPAMINE DOES NOT ENHANCE FUROSEMIDE-INDUCED NATRIURESIS IN PATIENTS WITH CONGESTIVE-HEART-FAILURE
Authors: VARGO DL BRATER DC RUDY DW SWAN SK
Citation: Dl. Vargo et al., DOPAMINE DOES NOT ENHANCE FUROSEMIDE-INDUCED NATRIURESIS IN PATIENTS WITH CONGESTIVE-HEART-FAILURE, Journal of the American Society of Nephrology, 7(7), 1996, pp. 1032-1037
USING ELECTRONIC MEDICAL RECORDS TO PREDICT MORTALITY IN PRIMARY-CAREPATIENTS WITH HEART-DISEASE - PROGNOSTIC POWER AND PATHOPHYSIOLOGIC IMPLICATIONS
Authors: TIERNEY WM TAKESUE BY VARGO DL ZHOU XH
Citation: Wm. Tierney et al., USING ELECTRONIC MEDICAL RECORDS TO PREDICT MORTALITY IN PRIMARY-CAREPATIENTS WITH HEART-DISEASE - PROGNOSTIC POWER AND PATHOPHYSIOLOGIC IMPLICATIONS, Journal of general internal medicine, 11(2), 1996, pp. 83-91
COMPUTERIZING GUIDELINES TO IMPROVE CARE AND PATIENT-OUTCOMES - THE EXAMPLE OF HEART-FAILURE
Authors: TIERNEY WM OVERHAGE JM TAKESUE BY HARRIS LE MURRAY MD VARGO DL MCDONALD CJ
Citation: Wm. Tierney et al., COMPUTERIZING GUIDELINES TO IMPROVE CARE AND PATIENT-OUTCOMES - THE EXAMPLE OF HEART-FAILURE, Journal of the American Medical Informatics Association, 2(5), 1995, pp. 316-322
DOPAMINE (DA) DOES NOT ENHANCE FUROSEMIDE (F)-INDUCED NATRIURESIS IN PATIENTS WITH COMPENSATED CONGESTIVE-HEART-FAILURE (CHF)
Authors: SWAN SK VARGO DL RUDY DL BRATER DC
Citation: Sk. Swan et al., DOPAMINE (DA) DOES NOT ENHANCE FUROSEMIDE (F)-INDUCED NATRIURESIS IN PATIENTS WITH COMPENSATED CONGESTIVE-HEART-FAILURE (CHF), Journal of the American Society of Nephrology, 6(3), 1995, pp. 477-477
BIOAVAILABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TORSEMIDE AND FUROSEMIDE IN PATIENTS WITH CONGESTIVE-HEART-FAILURE
Authors: VARGO DL KRAMER WG BLACK PK SMITH WB SERPAS T BRATER DC
Citation: Dl. Vargo et al., BIOAVAILABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TORSEMIDE AND FUROSEMIDE IN PATIENTS WITH CONGESTIVE-HEART-FAILURE, Clinical pharmacology and therapeutics, 57(6), 1995, pp. 601-609
BIOAVAILABILITY, PK AND PD OF TORSEMIDE AND FUROSEMIDE IN CHF PATIENTS
Authors: VARGO DL KRAMER WG BRATER DC
Citation: Dl. Vargo et al., BIOAVAILABILITY, PK AND PD OF TORSEMIDE AND FUROSEMIDE IN CHF PATIENTS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 141-141
THE PHARMACODYNAMICS OF TORSEMIDE IN CHF
Authors: VARGO DL BRATER DC KRAMER W
Citation: Dl. Vargo et al., THE PHARMACODYNAMICS OF TORSEMIDE IN CHF, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 201-201
Risultati: 1-9 |